呼吸系統藥物市場：依藥物類別、應用、通路和地區分類。

Pulmonary Drugs Market, By Drug Class, By Application, By Distribution Channel, By Geography

出版日期: 2026年02月10日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年呼吸系統藥物市場規模估計為566億美元，預計2033年將達到965億美元。預計2026年至2033年，該市場將以8.1%的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	566億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	8.10%	預計金額（2033 年）	965億美元

呼吸系統藥物用於治療肺部疾病。它們適用於多種病症，從普通感冒等輕微疾病到氣喘等慢性疾病。這些藥物有多種劑型，包括口服片劑、口服溶液、注射劑和吸入劑。吸入劑可將藥物直接輸送到肺部，直接作用於肺組織，以最大限度地減少全身副作用。

市場動態

推動呼吸系統藥物市場成長的關鍵因素包括慢性呼吸道疾病盛行率的上升、吸菸以及政府和非政府組織的各項措施。根據美國疾病管制與預防中心 (CDC) 統計，2015 年美國有 2500 萬人患有氣喘，這意味著每 13 個美國人中就有 1 人患有氣喘。在 18 歲以下族群中，氣喘患者達 620 萬人次。每年，因氣喘就診的醫師人數達 1,420 萬人次，急診就診人數達 180 萬人次。此外，品牌藥專利到期、研發投入增加以及創新產品的上市預計將成為預測期內市場成長的主要促進因素。例如，2017 年，葛蘭素史克 (GSK) 的專利三聯吸入劑 Trelegy Ellipta 獲得美國食品藥物食品藥物管理局)核准，用於治療慢性肺部疾病。 Trelegy Ellipta 將三種治療方法整合到一個吸入器中，為患者提供了一種新的治療選擇。然而，大量未確診的患者以及使用這些藥物可能產生的副作用（如腎損傷和其他不良後果）預計將限制市場成長。

本報告的主要特點

本報告對全球呼吸系統藥物市場進行了詳細分析，包括預測期（2026-2033 年）的市場規模和複合年成長率，以 2025 年為基準年。
此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本節根據以下參數介紹全球呼吸系統藥物市場主要企業的概況：公司概況、產品系列、主要亮點、財務績效和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球呼吸系統藥物市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球呼吸系統藥物市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析（3x3矩陣）
公司簡介
- Sanofi SA
- Meda Pharmaceuticals
- Circassia Pharmaceuticals Plc.
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Mallinckrodt Pharmaceuticals Plc.
- Cheisi Farmaceutici SpA
- Zambon Company SpA
- Alaxia SAS
- Merck Sharp &Dohme Limited

第9章

參考
分析方法

簡介目錄

Product Code: CMI1285

Pulmonary Drugs Market is estimated to be valued at USD 56.6 Bn in 2026 and is expected to reach USD 96.5 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 56.6 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.10%	2033 Value Projection:	USD 96.5 Bn

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

Market Dynamics

The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.

Key features of the study

This report provides in-depth analysis of pulmonary drugs market and provides market size (USD Bn) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2026 - 2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global pulmonary drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market

Market Segmentation

Drug Class Insights (Revenue, USD Bn, 2026 - 2033)
- Inhaled Corticosteroids
- Long Acting Beta-2 Agonists
- Antihistamines
- Vasodilators
- Short Acting Beta-2 Agonists
- Others
Application Insights (Revenue, USD Bn, 2026 - 2033)
- Asthma & COPD
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
- Others
Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Sanofi SA
- Meda Pharmaceuticals
- Circassia Pharmaceuticals Plc.
- AstraZenca Plc.
- GlaxoSmithKline Plc.
- Mallinckrodt Pharmaceuticals Plc.
- Cheisi farmaceutici S.p.A.
- Zambon Company S.p.A.
- Alaxia SAS
- Merck Sharp & Dohme Limited

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
Pipeline Analysis
Promotional Activities and Campaigns
Supply Chain Analysis
PEST Analysis
Epidemiology

4. Global Pulmonary Drugs Market, By Drug Class, 2026 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Inhaled Corticosteroids
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Long Acting Beta-2 Agonists
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Antihistamines
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Vasodilators
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Short Acting Beta-2 Agonists
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Pulmonary Drugs Market, By Application, 2026 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Asthma & COPD
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Allergic Rhinitis
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Pulmonary Arterial Hypertension
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Cystic Fibrosis
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Pulmonary Drugs Market, By Distribution Channel, 2026 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
E-Commerce
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

7. Global Pulmonary Drugs Market, By Region, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - UK
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis (3x3 Matrix)
Company Profiles
- Sanofi SA
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Meda Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Circassia Pharmaceuticals Plc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- AstraZeneca Plc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- GlaxoSmithKline Plc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Mallinckrodt Pharmaceuticals Plc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Cheisi Farmaceutici S.p.A
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Zambon Company S.p.A
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Alaxia SAS
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Merck Sharp & Dohme Limited
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
  - Analyst Views